<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Corentin Deckers</style></author><author><style face="normal" font="default" size="100%">Florian Bélik</style></author><author><style face="normal" font="default" size="100%">Denis, Olivier</style></author><author><style face="normal" font="default" size="100%">Isabel Montesinos</style></author><author><style face="normal" font="default" size="100%">Bogaerts, Pierre</style></author><author><style face="normal" font="default" size="100%">Jerina Boelens</style></author><author><style face="normal" font="default" size="100%">Laetitia Brassinne</style></author><author><style face="normal" font="default" size="100%">Julie Descy</style></author><author><style face="normal" font="default" size="100%">Stefanie Desmet</style></author><author><style face="normal" font="default" size="100%">Sarah Gils</style></author><author><style face="normal" font="default" size="100%">Bénédicte Lissoir</style></author><author><style face="normal" font="default" size="100%">Koen Magerman</style></author><author><style face="normal" font="default" size="100%">Veerle Matheeussen</style></author><author><style face="normal" font="default" size="100%">Cécile Meex</style></author><author><style face="normal" font="default" size="100%">Hector Rodriguez Villalobos</style></author><author><style face="normal" font="default" size="100%">Anne Marie Van den Abeele</style></author><author><style face="normal" font="default" size="100%">Kris Vernelen</style></author><author><style face="normal" font="default" size="100%">Pieter-Jan Ceyssens</style></author><author><style face="normal" font="default" size="100%">Huang, Te-Din</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">Belgian National Antibiogram Committee</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Multicenter interlaboratory study of routine systems for the susceptibility testing of temocillin using a challenge panel of multidrug-resistant strains.</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J Clin Microbiol Infect Dis</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023 Dec</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">42</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Accurate susceptibility result of temocillin (TMO) is important for treating infections caused by multidrug-resistant Enterobacterales. This multicenter study aimed to investigate the performance of routine temocillin testing assays against Enterobacterales challenging strains.&amp;nbsp;Forty-seven selected clinical isolates were blindly analyzed by 12 Belgian laboratories using VITEK® 2 (n = 5) and BD Phoenix™ (n = 3) automated systems, ETEST® gradient strip (n = 3), and disk (3 brands) diffusion method (DD; n = 6) for temocillin susceptibility using standardized methodology. Results were interpreted using EUCAST 2023 criteria and compared to the broth microdilution (BMD; Sensititre™ panel) method used as gold standard. Methods' reproducibility was assessed by testing 3 reference strains in triplicate.&amp;nbsp;A total of 702 organism-drug results were obtained against 33 TMO-susceptible and 14 TMO-resistant isolates. Excluding Proteae species (P. mirabilis and M. morganii), the essential agreement rates were excellent (91.5-100%) for all MIC-based methods. The highest category agreement was achieved by ETEST® (97.5%) followed by VITEK® 2 (93.2%), disk diffusion (91.6%), and BD Phoenix™ (88.5%). BD Phoenix™ and paper disk diffusion overcalled resistance (11.5% and 6.8% of major discrepancies, respectively), while ROSCO tablets diffusion and VITEK® 2 generated higher very major discrepancies (7.1% and 4.2% respectively). Inter-assay reproducibility was unsatisfactory using recommended E. coli ATCC 25922 strain but was excellent with E. coli ATCC 35218 and K. pneumoniae ATCC 700603 strains. This interlaboratory study suggests that routine testing methods provide accurate and reproducible TMO categorization results except for Proteae species.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">12</style></issue></record></records></xml>